版本:
中国

BRIEF-Sarepta Therapeutics says U.S. Commercial launch for Exondys 51 planned to commence immediately

Sept 19 (Reuters) -

* Sarepta therapeutics announces fda accelerated approval of exondys 51(tm) (eteplirsen) injection, an exon skipping therapy to treat duchenne muscular dystrophy (dmd) patients amenable to skipping exon 51

* Sarepta therapeutics inc says u.s. Commercial launch for exondys 51 planned to commence immediately Source text for Eikon:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐